Premium
In vivo induction of bone by recombinant human transforming growth factor β 1
Author(s) -
Beck L. Steven,
Ammann Arthur J.,
Aufdemorte Thomas B.,
Deguzman Leo,
Xu Yvette,
Lee Wyne P.,
McFatridge Lorrie A.,
Chen Theresa L.
Publication year - 1991
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650060910
Subject(s) - cartilage , in vivo , chemistry , growth factor , bone remodeling , transforming growth factor , endocrinology , anatomy , medicine , biology , microbiology and biotechnology , receptor
A single application of recombinant human transforming growth factor β 1 (rhTGF‐β 1 ) adjacent to cartilage was found to induce bone formation in rabbit ear full‐thickness skin wounds. At doses that optimally promote soft tissue healing, 25–100 ng rhTGF‐β 1 per wound caused osseous tissue formation starting 21 days after wounding to reach a peak incidence and area of bone formation at day 42. Bone formation was followed by active remodeling, resulting in lower incidence and area of bone formation at days 56 and 70. The early phase of bone formation was located overlying the cartilage and involved perichondrial cells that appeared to differentiate directly into osteoblasts forming bone matrix without a cartilage precursor. Cartilage was replaced with bone at later time points. rhTGF‐β 1 was able to increase the ratio of osteoblasts to osteoclasts lining the trabecular surface of bone and thus increase the net amount of bone formation. The present studies suggest a potential therapeutic role for rhTGF‐β 1 in hard tissue repair.